Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes

Author： Bak Ann Mosegaard   Egefjord Lærke   Gejl Michael   Steffensen Charlotte   Stecher Chalotte Willemann   Smidt Kamille   Brock Birgitte   Rungby Jørgen  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.15, Iss.10, 2011-10, pp. : 1153-1162

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes

By  

Current Pharmaceutical Design, Vol. 17, Iss. 38, 2011-01 ,pp. : 4379-4385

Bentham Science Publishers

Access to resources Recommend Favorite

Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection

By Hölscher Christian  

CNS Drugs, Vol. 26, Iss. 10, 2012-10 ,pp. : 871-882

Adis International

Access to resources Recommend Favorite

Incretin-Targeting Technologies for Type 2 Diabetes: Dipeptidyl Peptidase IV Inhibitors and Glucagon-Like Peptide-1 Analogs

By Adis International Limited  

Pharmaceutical & Diagnostic Innovation, Vol. 4, Iss. 7, 2006-07 ,pp. : 3-7

Adis International

Access to resources Recommend Favorite

Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1

By Holst J.J.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 9, 1999-09 ,pp. : 1409-1415

Informa Healthcare

Access to resources Recommend Favorite

Metformin increases the plasma level of glucagon-like peptide-1 (GLP-1) and does not inhibit dipeptidyl peptidase-IV

By  

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite